Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
View study Cerovecki T, Bojanic I, Brcic L, et al
STEP-1: Semaglutide 2,4 mg, the standard since 2021 The STEP-1 trial (Wilding et al., NEJM 2021, PMID 33567185) randomized 1,961 overweight or obese adults (BMI 30 or BMI 27 with comorbidities) without diabetes to semaglutide 2,4 mg/week or placebo, with lifestyle interventions administered concurrently in both arms
The first half of 2025 has confirmed a seismic shift in the pharmaceutical landscape: GLP-1 receptor agonists a class of new drug therapies for diabetes and obesity now dominate global sales charts
Research Applications and Protocol Examples Retatrutide is making waves in both metabolic and regenerative research, thanks to its triple receptor targeting
In aesthetic medicine, copper peptides are valued for their ability to stimulate collagen and elastin production , reduce inflammation, and enhance antioxidant defense mechanisms
Two murine GSTpi genes are arranged in tandem and are differentially expressed
US$ 20.07
US$ 20.20
US$ 27.98
US$ 21.16
